Polypeptides Having Dextranase Activity and Polynucleotides Encoding Same

ABSTRACT

The present invention relates to isolated polypeptides having dextranase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. application Ser. No. 14/782,162filed on Oct. 2, 2015, now pending, which is a 35 U.S.C. 371 nationalapplication of international application no. PCT/EP2014/056829 filedApr. 4, 2014, which claims priority or the benefit under 35 U.S.C. 119of European application no. 13162491.8 filed Apr. 5, 2013. The contentof these applications is fully incorporated herein by reference.

REFERENCE TO A SEQUENCE LISTING

This application contains a Sequence Listing in computer readable form,which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to polypeptides having dextranaseactivity, and polynucleotides encoding the polypeptides. The inventionalso relates to nucleic acid constructs, vectors, and host cellscomprising the polynucleotides as well as methods of producing and usingthe polypeptides.

Description of the Related Art

Dextran (polysaccharide with high molecular weight and predominantlystraight-chained glucose polymer with a majority of alpha-1-6 glucosidiclinkages) is highly undesirable impurity causing severe processingproblems in sugarcane mills and sugar beet mills as well as sugarrefineries.

The effects of the presence of dextran on sugar mill flow are numerousand varied (Imrie et al., 1972, Polysaccharides in sugar cane and itsproducts. Sugar Technology Reviews 1:291-361; Rauh et al., 1999,Analyzing Dextran in the Sugar Industry: A Review of Dextran in theFactory and a New Analytical Technique. 30th Biennial Meeting, AmericanSociety of Sugar Beet Technologists, 1999, Orlando, Fla., USA.;Eggleston et al., 2009, Application of dextranases in sugarcane factory:Overcoming practical, Sugar Tech. 11(2): 135-141), bringing aboutsignificant losses to the sugar industries: the raw sugar industry andthe refined sugar industry. Dextran is formed irreversibly from thesucrose contained in the raw materials (Cuddihy et al., 1998, Improvingsugar recovery with sugar process chemicals. Midland ResearchLaboratories, Inc.). The most significant impact of the dextrancontamination is on the viscosity of sugar processing streams. Dextranin raw juices causes poor clarification since it acts as a protectivecolloid inhibiting the coagulation phase in the decanter (Ravno et al.,2006, Dealing with dextran in the South African sugar industry,International Sugar Journal 108:255-269). As a result, more color andash are expected in the sugar made from such juice with fine suspendedmatter. Sugar refineries can face large challenges on the filtrationrates leading to reduced throughput due to the presence of thissuspended matter (Donavan, 1993, Raw sugar quality. The effect on therefiner, Proc. Sugar. Ind. Technol. 52: 117-130). The increasedviscosity caused by the dextran in sugar processing streams interferesnegatively on heat transfers rates, increases scale deposits onevaporators/heaters, lower molasses exhaustion and lower purgingefficiency in centrifuges (Geronimos et al., 1978. Viscosity increasesin concentrated sugar solutions and molasses due to dextrans. Inproceedings of the Queesland Society of Sugar Cane Technologist, 45^(th)Conference, Quaeesland, Australia, 119-126.; Singleton et al., 2001, Anew polarimetric method for the analysis of dextran and sucrose.International Sugar Journal 103(1230), 251-254; Kim et al., 2004,Determination of dextran in raw sugar process streams, Food Science andBiotechnology 13:248-252). The presence of dextran also influences therate of crystallization and causes elongation of sugars crystals(Covacevich et al., 1977. Studies on the effect of dextran structure oncane sugar crystal elongation and methods of analysis. In Proceedings ofthe XVI ISSCT Congress, Sao Paulo, SP, Brazil, 2493-2508) with severedrawbacks for the end chain factories of sugar (Vane, 1981, The effectof dextran on the distortion of hard candy, Proc. Sugar Ind. Technol.40: 95-102; Haynes et al., 2004, Dextran in refined sugar: impact onhard candy processing, Proc. Sugar Proc. Res. Inst. 138-146)). Thus, itcan be concluded that the benefits resulting in removal of dextraninclude viscosity decrease leading to increased sugar recovery and alsoto improve sugar quality. In particular, it is the high molecular massdextran (>10⁶ g/gmol) that has an impact on viscosity and handlingproperties of massecuites, and thus this is the type of dextran thatneeds to be targeted by the dextranase.

Dextranase is often added before the last evaporator when dextran levelsare high, or in juice tanks.

Several commercial Dextranase products are available, e.g., DextranasePlus L (Novozymes A/S) which is a dextranase from Chaetomium erraticum.

There is a need in the art for improved dextranase enzymes useful forreducing dextran content in sugar solutions in sugarcane mills, sugarbeet mills as well as sugar refineries.

SWISSPROT:B2MW82 discloses a dextranase from Talaromyces pinophilus.

The present invention provides polypeptides having dextranase activityand polynucleotides encoding the polypeptides.

SUMMARY OF THE INVENTION

The present invention relates to an isolated polypeptide havingdextranase activity, selected from the group consisting of:

(a) a polypeptide having at least 80%, at least 85%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% sequenceidentity to the mature polypeptide of SEQ ID NO: 2;

(b) a polypeptide encoded by a polynucleotide that hybridizes undermedium-high stringency conditions, high stringency conditions, or veryhigh stringency conditions with (i) the mature polypeptide codingsequence of SEQ ID NO: 1, or (ii) the full-length complement of (i);

(c) a polypeptide encoded by a polynucleotide having at least 80%, atleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99%, or 100% sequence identity to the mature polypeptide codingsequence of SEQ ID NO: 1;

(d) a variant of the mature polypeptide of SEQ ID NO: 2 comprising asubstitution, deletion, and/or insertion at one or more positions; and

(e) a fragment of the polypeptide of (a), (b), (c), or (d) that hasdextranase activity.

In a further aspect, the present invention relates to a compositioncomprising the polypeptide of the invention and a stabilizer.

In a still further aspect, the invention relates to a use of thedextranase of the invention, for reducing viscosity in a sugar solution.

In another further aspect, the invention relates to a method forreducing viscosity in a sugar solution comprising contacting the sugarsolution with a dextranase according to the invention.

The present invention also relates to isolated polynucleotides encodingthe polypeptides of the present invention; nucleic acid constructs;recombinant expression vectors; recombinant host cells comprising thepolynucleotides; compositions comprising the polypeptide of theinvention; and methods of producing the polypeptides.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the temperature activity profile for the dextranase of theinvention (T_(max)=62° C., pH=5.5).

FIG. 2 shows hydrolysis of dextran by dextranase followed by LC-MS. Themain products after day 6, correspond to glucose monosaccharide andtetrasaccharide. The glucose intensity reached the detector upper limitafter day 1. For each time point in the figure the columns represent (inthe same order): glucose, disaccharide, trisaccharide, tetrasacchariderespectively.

FIG. 3 shows proportionality between the measured pressure and viscosity(calibration curves) using the mViPr pipette. It shows dispensationmeasurements of pressure in Pascal [Pa] as a function of the actualviscosity [cp] of four viscosity standards (water and S6, N10, N35-Flukaviscosity and density standards) pipetting 200 μL using the 300 μLFinntip Extended tip (model: PMP-105-030J) at speed 4 and 5.

FIG. 4 shows the performance of the two dextranase enzymes, DextranasePlus L and the dextranase according to the invention, in reducingviscosity on synthetic syrup (50% w/w) enriched with dextran (0.5% w/v).The incubation condition was 55° C. for 20 min. The viscosity wasmeasured by the Vipr technology.

FIG. 5 shows the performance of dextranase enzymes in reducing viscosityon synthetic juice (15% w/w) enriched with dextran (0.25% w/v).Conditions: 55° C.; pH 5.5 (acetate buffer); 15 min. Protein dose: 0.025ppm (w/v). Comparison based on Dextrose Equivalent concept.

FIG. 6 Performance of dextranase enzymes in breaking down the dextrancontent on acetate buffer solution (pH 5.5) enriched with dextran (0.25%w/v). Conditions: 55° C.; pH 5.5; 15 min. Protein dose: 0.025 ppm (w/v).Comparison based on Dextrose Equivalent concept.

Definitions

Dextranase: The term “dextranase” means a glycoside hydrolase family 49activity (EC 3.2.1.11) that catalyzes the hydrolysis of the glycosidicbond between two or more carbohydrates, or between a carbohydrate and anoncarbohydrate moiety. The family GH49 dextranases hydrolysesalpha-1,6-glycosidic bonds in dextran polymers. For purposes of thepresent invention, dextranse activity is determined according to theprocedure described in the Examples. In one aspect, the polypeptides ofthe present invention have at least 20%, e.g., at least 40%, at least50%, at least 60%, at least 70%, at least 80%, at least 90%, at least95%, or at least 100% of the dextranase activity of the maturepolypeptide of SEQ ID NO: 2. Dextranase activity can be determinedaccording to the assay described in the examples (e.g., example 2).

Allelic variant: The term “allelic variant” means any of two or morealternative forms of a gene occupying the same chromosomal locus.Allelic variation arises naturally through mutation, and may result inpolymorphism within populations. Gene mutations can be silent (no changein the encoded polypeptide) or may encode polypeptides having alteredamino acid sequences. An allelic variant of a polypeptide is apolypeptide encoded by an allelic variant of a gene.

Catalytic domain: The term “catalytic domain” means the region of anenzyme containing the catalytic machinery of the enzyme.

cDNA: The term “cDNA” means a DNA molecule that can be prepared byreverse transcription from a mature, spliced, mRNA molecule obtainedfrom a eukaryotic or prokaryotic cell. cDNA lacks intron sequences thatmay be present in the corresponding genomic DNA. The initial, primaryRNA transcript is a precursor to mRNA that is processed through a seriesof steps, including splicing, before appearing as mature spliced mRNA.

Coding sequence: The term “coding sequence” means a polynucleotide,which directly specifies the amino acid sequence of a polypeptide. Theboundaries of the coding sequence are generally determined by an openreading frame, which begins with a start codon such as ATG, GTG, or TTGand ends with a stop codon such as TAA, TAG, or TGA. The coding sequencemay be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.

Control sequences: The term “control sequences” means nucleic acidsequences necessary for expression of a polynucleotide encoding a maturepolypeptide of the present invention. Each control sequence may benative (i.e., from the same gene) or foreign (i.e., from a differentgene) to the polynucleotide encoding the polypeptide or native orforeign to each other. Such control sequences include, but are notlimited to, a leader, polyadenylation sequence, propeptide sequence,promoter, signal peptide sequence, and transcription terminator. At aminimum, the control sequences include a promoter, and transcriptionaland translational stop signals. The control sequences may be providedwith linkers for the purpose of introducing specific restriction sitesfacilitating ligation of the control sequences with the coding region ofthe polynucleotide encoding a polypeptide.

Expression: The term “expression” includes any step involved in theproduction of a polypeptide including, but not limited to,transcription, post-transcriptional modification, translation,post-translational modification, and secretion.

Expression vector: The term “expression vector” means a linear orcircular DNA molecule that comprises a polynucleotide encoding apolypeptide and is operably linked to control sequences that provide forits expression.

Fragment: The term “fragment” means a polypeptide or a catalytic domainhaving one or more (e.g., several) amino acids absent from the aminoand/or carboxyl terminus of a mature polypeptide or domain; wherein thefragment has dextranase activity. In one aspect, a fragment contains atleast 570 amino acid residues (e.g., amino acids 25 to 594 of SEQ ID NO:2).

High stringency conditions: The term “high stringency conditions” meansfor probes of at least 100 nucleotides in length, prehybridization andhybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml shearedand denatured salmon sperm DNA, and 50% formamide, following standardSouthern blotting procedures for 12 to 24 hours. The carrier material isfinally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at65° C.

Host cell: The term “host cell” means any cell type that is susceptibleto transformation, transfection, transduction, or the like with anucleic acid construct or expression vector comprising a polynucleotideof the present invention. The term “host cell” encompasses any progenyof a parent cell that is not identical to the parent cell due tomutations that occur during replication.

Isolated: The term “isolated” means a substance in a form or environmentthat does not occur in nature. Non-limiting examples of isolatedsubstances include (1) any non-naturally occurring substance, (2) anysubstance including, but not limited to, any enzyme, variant, nucleicacid, protein, peptide or cofactor, that is at least partially removedfrom one or more or all of the naturally occurring constituents withwhich it is associated in nature; (3) any substance modified by the handof man relative to that substance found in nature; or (4) any substancemodified by increasing the amount of the substance relative to othercomponents with which it is naturally associated (e.g., multiple copiesof a gene encoding the substance; use of a stronger promoter than thepromoter naturally associated with the gene encoding the substance). Anisolated substance may be present in a fermentation broth sample.

Low stringency conditions: The term “low stringency conditions” meansfor probes of at least 100 nucleotides in length, prehybridization andhybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml shearedand denatured salmon sperm DNA, and 25% formamide, following standardSouthern blotting procedures for 12 to 24 hours. The carrier material isfinally washed three times each for 15 minutes using 2×SSC, 0.2% SDS at50° C.

Mature polypeptide: The term “mature polypeptide” means a polypeptide inits final form following translation and any post-translationalmodifications, such as N-terminal processing, C-terminal truncation,glycosylation, phosphorylation, etc. In one aspect, the maturepolypeptide is amino acids 17 to 594 of SEQ ID NO: 2 and amino acids 1to 16 of SEQ ID NO: 2 are a signal peptide. It is known in the art thata host cell may produce a mixture of two of more different maturepolypeptides (i.e., with a different C-terminal and/or N-terminal aminoacid) expressed by the same polynucleotide.

Mature polypeptide coding sequence: The term “mature polypeptide codingsequence” means a polynucleotide that encodes a mature polypeptidehaving dextranase activity. In one aspect, the mature polypeptide codingsequence is nucleotides 49 to 1782 of SEQ ID NO: 1 and nucleotides 1 to48 of SEQ ID NO: 1 encode a signal peptide.

Medium stringency conditions: The term “medium stringency conditions”means for probes of at least 100 nucleotides in length, prehybridizationand hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/mlsheared and denatured salmon sperm DNA, and 35% formamide, followingstandard Southern blotting procedures for 12 to 24 hours. The carriermaterial is finally washed three times each for 15 minutes using 2×SSC,0.2% SDS at 55° C.

Medium-high stringency conditions: The term “medium-high stringencyconditions” means for probes of at least 100 nucleotides in length,prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200micrograms/ml sheared and denatured salmon sperm DNA, and either 35%formamide, following standard Southern blotting procedures for 12 to 24hours. The carrier material is finally washed three times each for 15minutes using 2×SSC, 0.2% SDS at 60° C.

Nucleic acid construct: The term “nucleic acid construct” means anucleic acid molecule, either single- or double-stranded, which isisolated from a naturally occurring gene or is modified to containsegments of nucleic acids in a manner that would not otherwise exist innature or which is synthetic, which comprises one or more controlsequences.

Operably linked: The term “operably linked” means a configuration inwhich a control sequence is placed at an appropriate position relativeto the coding sequence of a polynucleotide such that the controlsequence directs expression of the coding sequence.

Sequence identity: The relatedness between two amino acid sequences orbetween two nucleotide sequences is described by the parameter “sequenceidentity”.

For purposes of the present invention, the sequence identity between twoamino acid sequences is determined using the Needleman-Wunsch algorithm(Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implementedin the Needle program of the EMBOSS package

(EMBOSS: The European Molecular Biology Open Software Suite, Rice etal., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 orlater. The parameters used are gap open penalty of 10, gap extensionpenalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62)substitution matrix. The output of Needle labeled “longest identity”(obtained using the—nobrief option) is used as the percent identity andis calculated as follows:

(Identical Residues×100)/(Length of Alignment−Total Number of Gaps inAlignment)

For purposes of the present invention, the sequence identity between twodeoxyribonucleotide sequences is determined using the Needleman-Wunschalgorithm (Needleman and Wunsch, 1970, supra) as implemented in theNeedle program of the EMBOSS package (EMBOSS: The European MolecularBiology Open Software Suite, Rice et al., 2000, supra), preferablyversion 5.0.0 or later. The parameters used are gap open penalty of 10,gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBINUC4.4) substitution matrix. The output of Needle labeled “longestidentity” (obtained using the—nobrief option) is used as the percentidentity and is calculated as follows:

(Identical Deoxyribonucleotides×100)/(Length of Alignment−Total Numberof Gaps in Alignment)

Subsequence: The term “subsequence” means a polynucleotide having one ormore (e.g., several) nucleotides absent from the 5′ and/or 3′ end of amature polypeptide coding sequence; wherein the subsequence encodes afragment having dextranase activity. In one embodiment the subsequencecorresponds to the polynucleotide encoding the catalytic domain. In oneaspect, a subsequence contains at least 1710 nucleotides (e.g.,nucleotides 73 to 1782 of SEQ ID NO: 1).

Variant: The term “variant” means a polypeptide having dextranaseactivity comprising an alteration, i.e., a substitution, insertion,and/or deletion, at one or more (e.g., several) positions. Asubstitution means replacement of the amino acid occupying a positionwith a different amino acid; a deletion means removal of the amino acidoccupying a position; and an insertion means adding an amino acidadjacent to and immediately following the amino acid occupying aposition.

Very high stringency conditions: The term “very high stringencyconditions” means for probes of at least 100 nucleotides in length,prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide,following standard Southern blotting procedures for 12 to 24 hours. Thecarrier material is finally washed three times each for 15 minutes using2×SSC, 0.2% SDS at 70° C.

Very low stringency conditions: The term “very low stringencyconditions” means for probes of at least 100 nucleotides in length,prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200micrograms/ml sheared and denatured salmon sperm DNA, and 25% formamide,following standard Southern blotting procedures for 12 to 24 hours. Thecarrier material is finally washed three times each for 15 minutes using2×SSC, 0.2% SDS at 45° C.

DETAILED DESCRIPTION OF THE INVENTION Polypeptides Having DextranaseActivity

In an embodiment, the present invention relates to isolated polypeptideshaving a sequence identity to the mature polypeptide of SEQ ID NO: 2 ofat least 80%, at least 85%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100%, which have dextranase activity. In oneaspect, the polypeptides differ by no more than 10 amino acids, e.g., 1,2, 3, 4, 5, 6, 7, 8, or 9, from the mature polypeptide of SEQ ID NO: 2.

In a particular embodiment, the invention relates to isolatedpolypeptides having a sequence identity to the mature polypeptide of SEQID NO: 2 of at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100%, and wherein thepolypeptide has at least 70% of the dextranase activity of the maturepolypeptide of SEQ ID NO: 2.

In a particular embodiment, the invention relates to isolatedpolypeptides having a sequence identity to the mature polypeptide of SEQID NO: 2 of at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100%, and wherein thepolypeptide has at least 80% of the dextranase activity of the maturepolypeptide of SEQ ID NO: 2.

In a particular embodiment, the invention relates to isolatedpolypeptides having a sequence identity to the mature polypeptide of SEQID NO: 2 of at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100%, and wherein thepolypeptide has at least 90% of the dextranase activity of the maturepolypeptide of SEQ ID NO: 2.

In a particular embodiment, the invention relates to isolatedpolypeptides having a sequence identity to the mature polypeptide of SEQID NO: 2 of at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100%, and wherein thepolypeptide has at least 95% of the dextranase activity of the maturepolypeptide of SEQ ID NO: 2.

In a particular embodiment, the invention relates to isolatedpolypeptides having a sequence identity to the mature polypeptide of SEQID NO: 2 of at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100%, and wherein thepolypeptide has at least 100% of the dextranase activity of the maturepolypeptide of SEQ ID NO: 2.

A polypeptide of the present invention preferably comprises or consistsof the amino acid sequence of SEQ ID NO: 2 or an allelic variantthereof; or is a fragment thereof having dextranase activity. In anotheraspect, the polypeptide comprises or consists of the mature polypeptideof SEQ ID NO: 2. In another aspect, the polypeptide comprises orconsists of amino acids 17 to 594 of SEQ ID NO: 2.

In another embodiment, the present invention relates to an isolatedpolypeptide having dextranase activity encoded by a polynucleotide thathybridizes under high stringency conditions, or very high stringencyconditions with (i) the mature polypeptide coding sequence of SEQ ID NO:1, or (ii) the full-length complement of (i) or (ii) (Sambrook et al.,1989, Molecular Cloning, A Laboratory Manual, 2d edition, Cold SpringHarbor, N.Y.).

The polynucleotide of SEQ ID NO: 1 or a subsequence thereof, as well asthe polypeptide of SEQ ID NO: 2 or a fragment thereof, may be used todesign nucleic acid probes to identify and clone DNA encodingpolypeptides having dextranase activity from strains of different generaor species according to methods well known in the art. In particular,such probes can be used for hybridization with the genomic DNA or cDNAof a cell of interest, following standard Southern blotting procedures,in order to identify and isolate the corresponding gene therein. Suchprobes can be considerably shorter than the entire sequence, but shouldbe at least 15, e.g., at least 25, at least 35, or at least 70nucleotides in length. Preferably, the nucleic acid probe is at least100 nucleotides in length, e.g., at least 200 nucleotides, at least 300nucleotides, at least 400 nucleotides, at least 500 nucleotides, atleast 600 nucleotides, at least 700 nucleotides, at least 800nucleotides, or at least 900 nucleotides in length. Both DNA and RNAprobes can be used. The probes are typically labeled for detecting thecorresponding gene (for example, with ³²P, ³H, ³⁵S, biotin, or avidin).Such probes are encompassed by the present invention.

A genomic DNA or cDNA library prepared from such other strains may bescreened for DNA that hybridizes with the probes described above andencodes a polypeptide having dextranase activity. Genomic or other DNAfrom such other strains may be separated by agarose or polyacrylamidegel electrophoresis, or other separation techniques. DNA from thelibraries or the separated DNA may be transferred to and immobilized onnitrocellulose or other suitable carrier material. In order to identifya clone or DNA that hybridizes with SEQ ID NO: 1 or a subsequencethereof, the carrier material is used in a Southern blot.

For purposes of the present invention, hybridization indicates that thepolynucleotide hybridizes to a labeled nucleic acid probe correspondingto (i) SEQ ID NO: 1; (ii) the mature polypeptide coding sequence of SEQID NO: 1; (iii) the full-length complement thereof; or (iv) asubsequence thereof; under very low to very high stringency conditions.Molecules to which the nucleic acid probe hybridizes under theseconditions can be detected using, for example, X-ray film or any otherdetection means known in the art.

In one aspect, the nucleic acid probe is a polynucleotide that encodesthe polypeptide of SEQ ID NO: 2; the mature polypeptide thereof; or afragment thereof. In another aspect, the nucleic acid probe is SEQ IDNO: 1.

In another embodiment, the present invention relates to an isolatedpolypeptide having dextranase activity encoded by a polynucleotidehaving a sequence identity to the mature polypeptide coding sequence ofSEQ ID NO: 1 of at least 80%, at least 85%, at least 90%, at least 91%,at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100%.

In another embodiment, the present invention relates to variants of themature polypeptide of SEQ ID NO: 2 comprising a substitution, deletion,and/or insertion at one or more (e.g., several) positions. In anembodiment, the number of amino acid substitutions, deletions and/orinsertions introduced into the mature polypeptide of SEQ ID NO: 2 is notmore than 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8 or 9. The amino acid changesmay be of a minor nature, that is conservative amino acid substitutionsor insertions that do not significantly affect the folding and/oractivity of the protein; small deletions, typically of 1-30 amino acids;small amino- or carboxyl-terminal extensions, such as an amino-terminalmethionine residue; a small linker peptide of up to 20-25 residues; or asmall extension that facilitates purification by changing net charge oranother function, such as a poly-histidine tract, an antigenic epitopeor a binding domain.

Examples of conservative substitutions are within the groups of basicamino acids (arginine, lysine and histidine), acidic amino acids(glutamic acid and aspartic acid), polar amino acids (glutamine andasparagine), hydrophobic amino acids (leucine, isoleucine and valine),aromatic amino acids (phenylalanine, tryptophan and tyrosine), and smallamino acids (glycine, alanine, serine, threonine and methionine). Aminoacid substitutions that do not generally alter specific activity areknown in the art and are described, for example, by H. Neurath and R. L.Hill, 1979, In, The Proteins, Academic Press, New York. Commonsubstitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr,Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile,Leu/Val, Ala/Glu, and Asp/Gly.

Alternatively, the amino acid changes are of such a nature that thephysico-chemical properties of the polypeptides are altered. Forexample, amino acid changes may improve the thermal stability of thepolypeptide, alter the substrate specificity, change the pH optimum, andthe like.

Essential amino acids in a polypeptide can be identified according toprocedures known in the art, such as site-directed mutagenesis oralanine-scanning mutagenesis (Cunningham and Wells, 1989, Science 244:1081-1085). In the latter technique, single alanine mutations areintroduced at every residue in the molecule, and the resultant mutantmolecules are tested for dextranase activity to identify amino acidresidues that are critical to the activity of the molecule. See also,Hilton et al., 1996, J. Biol. Chem. 271: 4699-4708. The active site ofthe enzyme or other biological interaction can also be determined byphysical analysis of structure, as determined by such techniques asnuclear magnetic resonance, crystallography, electron diffraction, orphotoaffinity labeling, in conjunction with mutation of putative contactsite amino acids. See, for example, de Vos et al., 1992, Science 255:306-312; Smith et al., 1992, J. Mol. Biol. 224: 899-904; Wlodaver etal., 1992, FEBS Lett. 309: 59-64. The identity of essential amino acidscan also be inferred from an alignment with a related polypeptide.

Single or multiple amino acid substitutions, deletions, and/orinsertions can be made and tested using known methods of mutagenesis,recombination, and/or shuffling, followed by a relevant screeningprocedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988,Science 241: 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can beused include error-prone PCR, phage display (e.g., Lowman et al., 1991,Biochemistry 30: 10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204), andregion-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Neret al., 1988, DNA 7: 127).

Mutagenesis/shuffling methods can be combined with high-throughput,automated screening methods to detect activity of cloned, mutagenizedpolypeptides expressed by host cells (Ness et al., 1999, NatureBiotechnology 17: 893-896). Mutagenized DNA molecules that encode activepolypeptides can be recovered from the host cells and rapidly sequencedusing standard methods in the art. These methods allow the rapiddetermination of the importance of individual amino acid residues in apolypeptide.

The polypeptide may be a hybrid polypeptide in which a region of onepolypeptide is fused at the N-terminus or the C-terminus of a region ofanother polypeptide.

The polypeptide may be a fusion polypeptide or cleavable fusionpolypeptide in which another polypeptide is fused at the N-terminus orthe C-terminus of the polypeptide of the present invention. A fusionpolypeptide is produced by fusing a polynucleotide encoding anotherpolypeptide to a polynucleotide of the present invention. Techniques forproducing fusion polypeptides are known in the art, and include ligatingthe coding sequences encoding the polypeptides so that they are in frameand that expression of the fusion polypeptide is under control of thesame promoter(s) and terminator. Fusion polypeptides may also beconstructed using intein technology in which fusion polypeptides arecreated post-translationally (Cooper et al., 1993, EMBO J. 12:2575-2583; Dawson et al., 1994, Science 266: 776-779).

A fusion polypeptide can further comprise a cleavage site between thetwo polypeptides. Upon secretion of the fusion protein, the site iscleaved releasing the two polypeptides. Examples of cleavage sitesinclude, but are not limited to, the sites disclosed in Martin et al.,2003, J. Ind. Microbiol. Biotechnol. 3: 568-576; Svetina et al., 2000,J. Biotechnol. 76: 245-251; Rasmussen-Wilson et al., 1997, Appl.Environ. Microbiol. 63: 3488-3493; Ward et al., 1995, Biotechnology 13:

498-503; and Contreras et al., 1991, Biotechnology 9: 378-381; Eaton etal., 1986, Biochemistry 25: 505-512; Collins-Racie et al., 1995,Biotechnology 13: 982-987; Carter et al., 1989, Proteins: Structure,Function, and Genetics 6: 240-248; and Stevens, 2003, Drug DiscoveryWorld 4: 35-48.

Sources of Polypeptides Having Dextranase Activity

A polypeptide having dextranase activity of the present invention may beobtained from fungi of the genus Acrophialophora. For purposes of thepresent invention, the term “obtained from” as used herein in connectionwith a given source shall mean that the polypeptide encoded by apolynucleotide is produced by the source or by a strain in which thepolynucleotide from the source has been inserted. In one aspect, thepolypeptide obtained from a given source is secreted extracellularly.

In one aspect, the polypeptide is an Acrophialophora polypeptide, e.g.,a polypeptide obtained from Acrophialophora fusispora, and, inparticular, a polypeptide obtained from Acrophialophora fusisporaCBS380.55.

Strains of this species are readily accessible to the public in a numberof culture collections, such as the American Type Culture Collection(ATCC), Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH(DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and AgriculturalResearch Service Patent Culture Collection, Northern Regional ResearchCenter (NRRL).

The polypeptide may be identified and obtained from other sourcesincluding microorganisms isolated from nature (e.g., soil, composts,water, etc.) or DNA samples obtained directly from natural materials(e.g., soil, composts, water, etc.) using the above-mentioned probes.Techniques for isolating microorganisms and DNA directly from naturalhabitats are well known in the art. A polynucleotide encoding thepolypeptide may then be obtained by similarly screening a genomic DNA orcDNA library of another microorganism or mixed DNA sample. Once apolynucleotide encoding a polypeptide has been detected with theprobe(s), the polynucleotide can be isolated or cloned by utilizingtechniques that are known to those of ordinary skill in the art (see,e.g., Sambrook et al., 1989, supra).

Catalytic Domains

In one embodiment, the present invention also relates to catalyticdomains having a sequence identity to amino acids 25 to 594 of SEQ IDNO: 2 of at least 80%, at least 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100%. In oneaspect, the catalytic domains comprise amino acid sequences that differby no more than 10 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9, fromamino acids 25 to 594 of SEQ ID NO: 2.

The catalytic domain preferably comprises or consists of amino acids 25to 594 of SEQ ID NO: 2 or an allelic variant thereof; or is a fragmentthereof having dextranase activity.

In another embodiment, the present invention also relates to catalyticdomains encoded by polynucleotides that hybridize under high stringencyconditions, or very high stringency conditions (as defined above) with(i) the nucleotides 73 to 1782 of SEQ ID NO: 1, or (ii) the full-lengthcomplement of (i) (Sambrook et al., 1989, supra).

In another embodiment, the present invention also relates to catalyticdomains encoded by polynucleotides having a sequence identity tonucleotides 73 to 1782 of SEQ ID NO: 1 of at least 80%, at least 85%, atleast 90%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99%, or 100%.

In another embodiment, the present invention also relates to catalyticdomain variants of amino acids 25 to 594 of SEQ ID NO: 2 comprising asubstitution, deletion, and/or insertion at one or more (e.g., several)positions. In one aspect, the number of amino acid substitutions,deletions and/or insertions introduced into the sequence of amino acids25 to 495 of SEQ ID NO: 2 is 10, e.g., 1, 2, 3, 4, 5, 6, 8, or 9.

Polynucleotides

The present invention also relates to isolated polynucleotides encodinga polypeptide, or a catalytic domain of the present invention, asdescribed herein.

The techniques used to isolate or clone a polynucleotide are known inthe art and include isolation from genomic DNA or cDNA, or a combinationthereof. The cloning of the polynucleotides from genomic DNA can beeffected, e.g., by using the well-known polymerase chain reaction (PCR)or antibody screening of expression libraries to detect cloned DNAfragments with shared structural features. See, e.g., Innis et al.,1990, PCR: A Guide to Methods and Application, Academic Press, New York.Other nucleic acid amplification procedures such as ligase chainreaction (LCR), ligation activated transcription (LAT) andpolynucleotide-based amplification (NASBA) may be used. Thepolynucleotides may be cloned from a strain of Acrophialophora, or arelated organism and thus, for example, may be an allelic or speciesvariant of the polypeptide encoding region of the polynucleotide.

Modification of a polynucleotide encoding a polypeptide of the presentinvention may be necessary for synthesizing polypeptides substantiallysimilar to the polypeptide. The term “substantially similar” to thepolypeptide refers to non-naturally occurring forms of the polypeptide.These polypeptides may differ in some engineered way from thepolypeptide isolated from its native source, e.g., variants that differin specific activity, thermostability, pH optimum, or the like. Thevariants may be constructed on the basis of the polynucleotide presentedas the mature polypeptide coding sequence of SEQ ID NO: 1, e.g., asubsequence thereof, and/or by introduction of nucleotide substitutionsthat do not result in a change in the amino acid sequence of thepolypeptide, but which correspond to the codon usage of the hostorganism intended for production of the enzyme, or by introduction ofnucleotide substitutions that may give rise to a different amino acidsequence. For a general description of nucleotide substitution, see,e.g., Ford et al., 1991, Protein Expression and Purification 2: 95-107.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprisinga polynucleotide of the present invention operably linked to one or morecontrol sequences that direct the expression of the coding sequence in asuitable host cell under conditions compatible with the controlsequences.

A polynucleotide may be manipulated in a variety of ways to provide forexpression of the polypeptide. Manipulation of the polynucleotide priorto its insertion into a vector may be desirable or necessary dependingon the expression vector. The techniques for modifying polynucleotidesutilizing recombinant DNA methods are well known in the art.

The control sequence may be a promoter, a polynucleotide that isrecognized by a host cell for expression of a polynucleotide encoding apolypeptide of the present invention. The promoter containstranscriptional control sequences that mediate the expression of thepolypeptide. The promoter may be any polynucleotide that showstranscriptional activity in the host cell including mutant, truncated,and hybrid promoters, and may be obtained from genes encodingextracellular or intracellular polypeptides either homologous orheterologous to the host cell.

Examples of suitable promoters for directing transcription of thenucleic acid constructs of the present invention in a filamentous fungalhost cell are promoters obtained from the genes for Aspergillus nidulansacetamidase, Aspergillus niger neutral alpha-amylase, Aspergillus nigeracid stable alpha-amylase, Aspergillus niger or Aspergillus awamoriglucoamylase (glaA), Aspergillus oryzae TAKA amylase, Aspergillus oryzaealkaline protease, Aspergillus oryzae triose phosphate isomerase,Fusarium oxysporum trypsin-like protease (WO 96/00787), Fusariumvenenatum amyloglucosidase (WO 00/56900), Fusarium venenatum Daria (WO00/56900), Fusarium venenatum Quinn (WO 00/56900), Rhizomucor mieheilipase, Rhizomucor miehei aspartic proteinase, Trichoderma reeseibeta-glucosidase, Trichoderma reesei cellobiohydrolase I, Trichodermareesei cellobiohydrolase II, Trichoderma reesei endoglucanase I,Trichoderma reesei endoglucanase II, Trichoderma reesei endoglucanaseIII, Trichoderma reesei endoglucanase IV, Trichoderma reeseiendoglucanase V, Trichoderma reesei xylanase I, Trichoderma reeseixylanase II, Trichoderma reesei beta-xylosidase, as well as the NA2-tpipromoter (a modified promoter from an Aspergillus neutral alpha-amylasegene in which the untranslated leader has been replaced by anuntranslated leader from an Aspergillus triose phosphate isomerase gene;non-limiting examples include modified promoters from an Aspergillusniger neutral alpha-amylase gene in which the untranslated leader hasbeen replaced by an untranslated leader from an Aspergillus nidulans orAspergillus oryzae triose phosphate isomerase gene); and mutant,truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiaegalactokinase (GAL1), Saccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP),Saccharomyces cerevisiae triose phosphate isomerase (TPI), Saccharomycescerevisiae metallothionein (CUP1), and Saccharomyces cerevisiae3-phosphoglycerate kinase. Other useful promoters for yeast host cellsare described by Romanos et al., 1992, Yeast 8: 423-488.

The control sequence may also be a transcription terminator, which isrecognized by a host cell to terminate transcription. The terminator isoperably linked to the 3′-terminus of the polynucleotide encoding thepolypeptide. Any terminator that is functional in the host cell may beused in the present invention.

Preferred terminators for filamentous fungal host cells are obtainedfrom the genes for Aspergillus nidulans anthranilate synthase,Aspergillus niger glucoamylase, Aspergillus niger alpha-glucosidase,Aspergillus oryzae TAKA amylase, and Fusarium oxysporum trypsin-likeprotease.

Preferred terminators for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae enolase, Saccharomyces cerevisiaecytochrome C (CYC1), and Saccharomyces cerevisiaeglyceraldehyde-3-phosphate dehydrogenase. Other useful terminators foryeast host cells are described by Romanos et al., 1992, supra.

The control sequence may also be an mRNA stabilizer region downstream ofa promoter and upstream of the coding sequence of a gene which increasesexpression of the gene.

Examples of suitable mRNA stabilizer regions are obtained from aBacillus thuringiensis cryIIIA gene (WO 94/25612) and a Bacillussubtilis SP82 gene (Hue et al., 1995, Journal of Bacteriology 177:3465-3471).

The control sequence may also be a leader, a nontranslated region of anmRNA that is important for translation by the host cell. The leader isoperably linked to the 5′-terminus of the polynucleotide encoding thepolypeptide. Any leader that is functional in the host cell may be used.

Preferred leaders for filamentous fungal host cells are obtained fromthe genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulanstriose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, andSaccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequenceoperably linked to the 3′-terminus of the polynucleotide and, whentranscribed, is recognized by the host cell as a signal to addpolyadenosine residues to transcribed mRNA. Any polyadenylation sequencethat is functional in the host cell may be used.

Preferred polyadenylation sequences for filamentous fungal host cellsare obtained from the genes for Aspergillus nidulans anthranilatesynthase, Aspergillus niger glucoamylase, Aspergillus nigeralpha-glucosidase Aspergillus oryzae TAKA amylase, and Fusariumoxysporum trypsin-like protease.

Useful polyadenylation sequences for yeast host cells are described byGuo and Sherman, 1995, Mol. Cellular Biol. 15: 5983-5990.

The control sequence may also be a signal peptide coding region thatencodes a signal peptide linked to the N-terminus of a polypeptide anddirects the polypeptide into the cell's secretory pathway. The 5′-end ofthe coding sequence of the polynucleotide may inherently contain asignal peptide coding sequence naturally linked in translation readingframe with the segment of the coding sequence that encodes thepolypeptide. Alternatively, the 5′-end of the coding sequence maycontain a signal peptide coding sequence that is foreign to the codingsequence. A foreign signal peptide coding sequence may be required wherethe coding sequence does not naturally contain a signal peptide codingsequence. Alternatively, a foreign signal peptide coding sequence maysimply replace the natural signal peptide coding sequence in order toenhance secretion of the polypeptide. However, any signal peptide codingsequence that directs the expressed polypeptide into the secretorypathway of a host cell may be used.

Effective signal peptide coding sequences for filamentous fungal hostcells are the signal peptide coding sequences obtained from the genesfor Aspergillus niger neutral amylase, Aspergillus niger glucoamylase,Aspergillus oryzae TAKA amylase, Humicola insolens cellulase, Humicolainsolens endoglucanase V, Humicola lanuginosa lipase, and Rhizomucormiehei aspartic proteinase.

Useful signal peptides for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiaeinvertase. Other useful signal peptide coding sequences are described byRomanos et al., 1992, supra.

The control sequence may also be a propeptide coding sequence thatencodes a propeptide positioned at the N-terminus of a polypeptide. Theresultant polypeptide is known as a proenzyme or propolypeptide (or azymogen in some cases). A propolypeptide is generally inactive and canbe converted to an active polypeptide by catalytic or autocatalyticcleavage of the propeptide from the propolypeptide. The propeptidecoding sequence may be obtained from the genes for Bacillus subtilisalkaline protease (aprE), Bacillus subtilis neutral protease (nprT),Myceliophthora thermophila laccase (WO 95/33836), Rhizomucor mieheiaspartic proteinase, and Saccharomyces cerevisiae alpha-factor.

Where both signal peptide and propeptide sequences are present, thepropeptide sequence is positioned next to the N-terminus of apolypeptide and the signal peptide sequence is positioned next to theN-terminus of the propeptide sequence.

It may also be desirable to add regulatory sequences that regulateexpression of the polypeptide relative to the growth of the host cell.Examples of regulatory systems are those that cause expression of thegene to be turned on or off in response to a chemical or physicalstimulus, including the presence of a regulatory compound. Regulatorysystems in prokaryotic systems include the lac, tac, and trp operatorsystems. In yeast, the ADH2 system or GAL1 system may be used. Infilamentous fungi, the Aspergillus niger glucoamylase promoter,Aspergillus oryzae TAKA alpha-amylase promoter, and Aspergillus oryzaeglucoamylase promoter may be used. Other examples of regulatorysequences are those that allow for gene amplification. In eukaryoticsystems, these regulatory sequences include the dihydrofolate reductasegene that is amplified in the presence of methotrexate, and themetallothionein genes that are amplified with heavy metals. In thesecases, the polynucleotide encoding the polypeptide would be operablylinked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectorscomprising a polynucleotide of the present invention, a promoter, andtranscriptional and translational stop signals. The various nucleotideand control sequences may be joined together to produce a recombinantexpression vector that may include one or more convenient restrictionsites to allow for insertion or substitution of the polynucleotideencoding the polypeptide at such sites. Alternatively, thepolynucleotide may be expressed by inserting the polynucleotide or anucleic acid construct comprising the polynucleotide into an appropriatevector for expression. In creating the expression vector, the codingsequence is located in the vector so that the coding sequence isoperably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid orvirus) that can be conveniently subjected to recombinant DNA proceduresand can bring about expression of the polynucleotide. The choice of thevector will typically depend on the compatibility of the vector with thehost cell into which the vector is to be introduced. The vector may be alinear or closed circular plasmid.

The vector may be an autonomously replicating vector, i.e., a vectorthat exists as an extrachromosomal entity, the replication of which isindependent of chromosomal replication, e.g., a plasmid, anextrachromosomal element, a minichromosome, or an artificial chromosome.The vector may contain any means for assuring self-replication.Alternatively, the vector may be one that, when introduced into the hostcell, is integrated into the genome and replicated together with thechromosome(s) into which it has been integrated. Furthermore, a singlevector or plasmid or two or more vectors or plasmids that togethercontain the total DNA to be introduced into the genome of the host cell,or a transposon, may be used.

The vector preferably contains one or more selectable markers thatpermit easy selection of transformed, transfected, transduced, or thelike cells. A selectable marker is a gene the product of which providesfor biocide or viral resistance, resistance to heavy metals, prototrophyto auxotrophs, and the like.

Examples of bacterial selectable markers are Bacillus licheniformis orBacillus subtilis dal genes, or markers that confer antibioticresistance such as ampicillin, chloramphenicol, kanamycin, neomycin,spectinomycin, or tetracycline resistance. Suitable markers for yeasthost cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2,MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungalhost cell include, but are not limited to, amdS (acetamidase), argB(ornithine carbamoyltransferase), bar (phosphinothricinacetyltransferase), hph (hygromycin phosphotransferase), niaD (nitratereductase), pyrG (orotidine-5′-phosphate decarboxylase), sC (sulfateadenyltransferase), and trpC (anthranilate synthase), as well asequivalents thereof. Preferred for use in an Aspergillus cell areAspergillus nidulans or Aspergillus oryzae amdS and pyrG genes and aStreptomyces hygroscopicus bar gene.

The vector preferably contains an element(s) that permits integration ofthe vector into the host cell's genome or autonomous replication of thevector in the cell independent of the genome.

For integration into the host cell genome, the vector may rely on thepolynucleotide's sequence encoding the polypeptide or any other elementof the vector for integration into the genome by homologous ornon-homologous recombination. Alternatively, the vector may containadditional polynucleotides for directing integration by homologousrecombination into the genome of the host cell at a precise location(s)in the chromosome(s). To increase the likelihood of integration at aprecise location, the integrational elements should contain a sufficientnumber of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000base pairs, and 800 to 10,000 base pairs, which have a high degree ofsequence identity to the corresponding target sequence to enhance theprobability of homologous recombination. The integrational elements maybe any sequence that is homologous with the target sequence in thegenome of the host cell. Furthermore, the integrational elements may benon-encoding or encoding polynucleotides. On the other hand, the vectormay be integrated into the genome of the host cell by non-homologousrecombination.

For autonomous replication, the vector may further comprise an origin ofreplication enabling the vector to replicate autonomously in the hostcell in question. The origin of replication may be any plasmidreplicator mediating autonomous replication that functions in a cell.The term “origin of replication” or “plasmid replicator” means apolynucleotide that enables a plasmid or vector to replicate in vivo.

Examples of bacterial origins of replication are the origins ofreplication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permittingreplication in E. coli, and pUB110, pE194, pTA1060, and pAMβ1 permittingreplication in Bacillus.

Examples of origins of replication for use in a yeast host cell are the2 micron origin of replication, ARS1, ARS4, the combination of ARS1 andCEN3, and the combination of ARS4 and CEN6.

Examples of origins of replication useful in a filamentous fungal cellare AMA1 and ANSI (Gems et al., 1991, Gene 98: 61-67; Cullen et al.,1987, Nucleic Acids Res. 15: 9163-9175; WO 00/24883). Isolation of theAMA1 gene and construction of plasmids or vectors comprising the genecan be accomplished according to the methods disclosed in WO 00/24883.

More than one copy of a polynucleotide of the present invention may beinserted into a host cell to increase production of a polypeptide. Anincrease in the copy number of the polynucleotide can be obtained byintegrating at least one additional copy of the sequence into the hostcell genome or by including an amplifiable selectable marker gene withthe polynucleotide where cells containing amplified copies of theselectable marker gene, and thereby additional copies of thepolynucleotide, can be selected for by cultivating the cells in thepresence of the appropriate selectable agent.

The procedures used to ligate the elements described above to constructthe recombinant expression vectors of the present invention are wellknown to one skilled in the art (see, e.g., Sambrook et al., 1989,supra).

Host Cells

The present invention also relates to recombinant host cells, comprisinga polynucleotide of the present invention operably linked to one or morecontrol sequences that direct the production of a polypeptide of thepresent invention. A construct or vector comprising a polynucleotide isintroduced into a host cell so that the construct or vector ismaintained as a chromosomal integrant or as a self-replicatingextra-chromosomal vector as described earlier. The term “host cell”encompasses any progeny of a parent cell that is not identical to theparent cell due to mutations that occur during replication. The choiceof a host cell will to a large extent depend upon the gene encoding thepolypeptide and its source.

The host cell may be any cell useful in the recombinant production of apolypeptide of the present invention, e.g., a prokaryote or a eukaryote.

The host cell may also be a eukaryote, such as a mammalian, insect,plant, or fungal cell.

The host cell may be a fungal cell. “Fungi” as used herein includes thephyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota as wellas the Oomycota and all mitosporic fungi (as defined by Hawksworth etal., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition,1995, CAB International, University Press, Cambridge, UK).

The fungal host cell may be a yeast cell. “Yeast” as used hereinincludes ascosporogenous yeast (Endomycetales), basidiosporogenousyeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes).Since the classification of yeast may change in the future, for thepurposes of this invention, yeast shall be defined as described inBiology and Activities of Yeast (Skinner, Passmore, and Davenport,editors, Soc. App. Bacteriol. Symposium Series No. 9, 1980).

The yeast host cell may be a Candida, Hansenula, Kluyveromyces, Pichia,Saccharomyces, Schizosaccharomyces, or Yarrowia cell, such as aKluyveromyces lactis, Saccharomyces carisbergensis, Saccharomycescerevisiae, Saccharomyces diastaticus, Saccharomyces douglasii,Saccharomyces kluyveri, Saccharomyces norbensis, Saccharomycesoviformis, or Yarrowia lipolytica cell.

The fungal host cell may be a filamentous fungal cell. “Filamentousfungi” include all filamentous forms of the subdivision Eumycota andOomycota (as defined by Hawksworth et al., 1995, supra). The filamentousfungi are generally characterized by a mycelial wall composed of chitin,cellulose, glucan, chitosan, mannan, and other complex polysaccharides.Vegetative growth is by hyphal elongation and carbon catabolism isobligately aerobic. In contrast, vegetative growth by yeasts such asSaccharomyces cerevisiae is by budding of a unicellular thallus andcarbon catabolism may be fermentative.

The filamentous fungal host cell may be an Acremonium, Aspergillus,Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus,Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe,Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces,Penicillium, Phanerochaete, Phiebia, Piromyces, Pleurotus,Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium,Trametes, or Trichoderma cell.

For example, the filamentous fungal host cell may be an Aspergillusawamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillusjaponicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae,Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea,Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsisrivulosa, Ceriporiopsis subrufa, Ceriporiopsis subvermispora,Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporiumlucknowense, Chrysosporium merdarium, Chrysosporium pannicola,Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporiumzonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium bactridioides,Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusariumgraminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi,Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusariumsambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusariumsuiphureum, Fusarium torulosum, Fusarium trichothecioides, Fusariumvenenatum, Humicola insolens, Humicola lanuginosa, Mucor miehei,Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum,Phanerochaete chrysosporium, Phlebia radiata, Pleurotus eryngii,Thielavia terrestris, Trametes villosa, Trametes versicolor, Trichodermaharzianum, Trichoderma koningii, Trichoderma longibrachiatum,Trichoderma reesei, or Trichoderma viride cell.

Fungal cells may be transformed by a process involving protoplastformation, transformation of the protoplasts, and regeneration of thecell wall in a manner known per se. Suitable procedures fortransformation of Aspergillus and Trichoderma host cells are describedin EP 238023, Yelton et al., 1984, Proc. Natl. Acad. Sci. USA 81:1470-1474, and Christensen et al., 1988, Bio/Technology 6: 1419-1422.Suitable methods for transforming Fusarium species are described byMalardier et al., 1989, Gene 78: 147-156, and WO 96/00787. Yeast may betransformed using the procedures described by Becker and Guarente, InAbelson, J. N. and Simon, M. I., editors, Guide to Yeast Genetics andMolecular Biology, Methods in Enzymology, Volume 194, pp 182-187,Academic Press, Inc., New York; Ito et al., 1983, J. Bacteriol. 153:163; and Hinnen et al., 1978, Proc. Natl. Acad. Sci. USA 75: 1920.

Methods of Production

The present invention also relates to methods of producing a polypeptideof the present invention, comprising (a) cultivating a cell, which inits wild-type form produces the polypeptide, under conditions conducivefor production of the polypeptide; and (b) recovering the polypeptide.In a preferred aspect, the cell is an Acrophialophora cell. In a morepreferred aspect, the cell is an Acrophialophora fusispora cell. In amost preferred aspect, the cell is Acrophialophora fusispora CBS380.55.

The present invention also relates to methods of producing a polypeptideof the present invention, comprising (a) cultivating a recombinant hostcell of the present invention under conditions conducive for productionof the polypeptide; and (b) recovering the polypeptide.

The host cells are cultivated in a nutrient medium suitable forproduction of the polypeptide using methods known in the art. Forexample, the cell may be cultivated by shake flask cultivation, orsmall-scale or large-scale fermentation (including continuous, batch,fed-batch, or solid state fermentations) in laboratory or industrialfermentors performed in a suitable medium and under conditions allowingthe polypeptide to be expressed and/or isolated. The cultivation takesplace in a suitable nutrient medium comprising carbon and nitrogensources and inorganic salts, using procedures known in the art. Suitablemedia are available from commercial suppliers or may be preparedaccording to published compositions (e.g., in catalogues of the AmericanType Culture Collection). If the polypeptide is secreted into thenutrient medium, the polypeptide can be recovered directly from themedium. If the polypeptide is not secreted, it can be recovered fromcell lysates.

The polypeptide may be detected using methods known in the art that arespecific for the polypeptides. These detection methods include, but arenot limited to, use of specific antibodies, formation of an enzymeproduct, or disappearance of an enzyme substrate. For example, an enzymeassay may be used to determine the activity of the polypeptide.

The polypeptide may be recovered using methods known in the art. Forexample, the polypeptide may be recovered from the nutrient medium byconventional procedures including, but not limited to, collection,centrifugation, filtration, extraction, spray-drying, evaporation, orprecipitation.

The polypeptide may be purified by a variety of procedures known in theart including, but not limited to, chromatography (e.g., ion exchange,affinity, hydrophobic, chromatofocusing, and size exclusion),electrophoretic procedures (e.g., preparative isoelectric focusing),differential solubility (e.g., ammonium sulfate precipitation),SDS-PAGE, or extraction (see, e.g., Protein Purification, Janson andRyden, editors, VCH Publishers, New York, 1989) to obtain substantiallypure polypeptides.

In an alternative aspect, the polypeptide is not recovered, but rather ahost cell of the present invention expressing the polypeptide is used asa source of the polypeptide.

Compositions

The present invention in a further embodiment relates to compositionscomprising the dextranase according to the invention. Such compositionsmay further comprise a stabilizer. The stabilizer may in one embodimentbe selected from glycerol and trisodium citrate dihydrate.

Uses

In a particular embodiment according to the invention, the dextranase iscontemplated for use in the sugar cane industry for removingdextran/reducing viscosity from various sugar solutions.

In one aspect, the invention relates to a use of the dextranase of theinvention, for reducing viscosity in a sugar solution.

In a further aspect, the invention relates to a method for reducingviscosity in a sugar solution comprising contacting the sugar solutionwith a dextranase according to the invention.

Sugar solution: In the present context, a “sugar solution” means anysolution comprising sugar derived from either sugar cane or sugar beet.In particular the sugar solution is selected from the group comprisingany juice (including primary juice, secondary juice, mixed juice,sulphittated juice, limed juice, decanted juice, filtered juice,evaporated juice, concentrated juice, or juices derived from unitoperations of sugarcane mills, beet sugar mills or sugar refinery), anysyrup (concentrated syrup, sulphitated sugar, floated syrup, limedsyrup, syrup derived from unit operation of sugarcane mills, sugar beetindustry or sugar refinery), any massacuite (massacuite A, massacuite B,massacuite C), any molasses, any magma, raw sugar solution, and/or VHPsugar solution, also affinated sugar, melted sugar, clarified sugar,carbonated sugar, phosphatated sugar, (including any sugar solutionderived from unit operation of sugar refinery).

The dextranase may be added at any suitable step during the raw sugarproduction process. In particular, the dextranase may be added to thesugar cane juice before or during clarification. Other suitable pointsto add dextranase could be to the holding sugar juice tanks or to syruptanks. In another particular embodiment, the dextranase is added duringthe evaporation step, e.g., to the melasse stream between evaporators,more particularly prior to the last evaporator.

The dextranase according to the invention has a pH activity profilesuitable applications in a pH range from 4.0 to 8.0, particularly from5.0 to 7.0, more particularly from 5.5 to 6.5.

The dextranase according to the invention further has an optimaltemperature profile in the range from 30° C. to 65° C. Preferable thedextranase is therefore applied in the methods of the present inventionin the range from 30-65° C., particularly from 40-65° C., moreparticularly from 50-65° C.

The present invention is further described by the following numberedparagraphs.

-   Paragraph [1]. An isolated polypeptide having dextranase activity,    selected from the group consisting of:

(a) a polypeptide having at least 80%, at least 85%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, at least 99%, or 100% sequenceidentity to the mature polypeptide of SEQ ID NO: 2;

(b) a polypeptide encoded by a polynucleotide that hybridizes undermedium-high stringency conditions, high stringency conditions, or veryhigh stringency conditions with (i) the mature polypeptide codingsequence of SEQ ID NO: 1, or (ii) the full-length complement of (i);

(c) a polypeptide encoded by a polynucleotide having at least 80%, atleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99%, or 100% sequence identity to the mature polypeptide codingsequence of SEQ ID NO: 1;

(d) a variant of the mature polypeptide of SEQ ID NO: 2 comprising asubstitution, deletion, and/or insertion at one or several positions;and

(e) a fragment of the polypeptide of (a), (b), (c), or (d) that hasdextranase activity.

-   Paragraph [2]. The polypeptide of paragraph 1, having at least 80%,    at least 85%, at least 90%, at least 91%, at least 92%, at least    93%, at least 94%, at least 95%, at least 96%, at least 97%, at    least 98%, at least 99% or 100% sequence identity to the mature    polypeptide of SEQ ID NO: 2.-   Paragraph [3]. The polypeptide of paragraph 2, having least 80%, at    least 85%, at least 90%, at least 91%, at least 92%, at least 93%,    at least 94%, at least 95%, at least 96%, at least 97%, at least    98%, at least 99%, or 100%, and wherein the polypeptide has at least    at least 70% of the dextranase activity of the mature polypeptide of    SEQ ID NO: 2.-   Paragraph [4]. The polypeptide of paragraph 2, having least 80%, at    least 85%, at least 90%, at least 91%, at least 92%, at least 93%,    at least 94%, at least 95%, at least 96%, at least 97%, at least    98%, at least 99%, or 100%, and wherein the polypeptide has at least    at least 80% of the dextranase activity of the mature polypeptide of    SEQ ID NO: 2.-   Paragraph [5]. The polypeptide of paragraph 2, having least 80%, at    least 85%, at least 90%, at least 91%, at least 92%, at least 93%,    at least 94%, at least 95%, at least 96%, at least 97%, at least    98%, at least 99%, or 100%, and wherein the polypeptide has at least    90% of the dextranase activity of the mature polypeptide of SEQ ID    NO: 2.-   Paragraph [6]. The polypeptide of paragraph 2, having least 80%, at    least 85%, at least 90%, at least 91%, at least 92%, at least 93%,    at least 94%, at least 95%, at least 96%, at least 97%, at least    98%, at least 99%, or 100%, and wherein the polypeptide has at least    at least 95% of the dextranase activity of the mature polypeptide of    SEQ ID NO: 2.-   Paragraph [7]. The polypeptide of paragraph 2, having least 80%, at    least 85%, at least 90%, at least 91%, at least 92%, at least 93%,    at least 94%, at least 95%, at least 96%, at least 97%, at least    98%, at least 99%, or 100%, and wherein the polypeptide has at least    100% of the dextranase activity of the mature polypeptide of SEQ ID    NO: 2.-   Paragraph [8]. The polypeptide of paragraph 1, which is encoded by a    polynucleotide that hybridizes under high stringency conditions, or    very high stringency conditions with (i) the mature polypeptide    coding sequence of SEQ ID NO: 1, or (ii) the full-length complement    of (i).-   Paragraph [9]. The polypeptide of paragraphs 1, which is encoded by    a polynucleotide having at least 80%, at least 85%, at least 90%, at    least 91%, at least 92%, at least 93%, at least 94%, at least 95%,    at least 96%, at least 97%, at least 98%, at least 99% or 100%    sequence identity to the mature polypeptide coding sequence of SEQ    ID NO: 1.-   Paragraph [10]. The polypeptide of any of paragraphs 1-9, comprising    or consisting of SEQ ID NO: 2 or the mature polypeptide of SEQ ID    NO: 2.-   Paragraph [11]. The polypeptide of paragraph 10, wherein the mature    polypeptide is amino acids 17 to 594 of SEQ ID NO: 2.-   Paragraph [12]. The polypeptide of any of paragraphs 1-11, which is    a variant of the mature polypeptide of SEQ ID NO: 2 comprising a    substitution, deletion, and/or insertion at one or several    positions.-   Paragraph [13]. The polypeptide of any of paragraphs 1-12, which is    a fragment of SEQ ID NO: 2, wherein the fragment has dextranase    activity.-   Paragraph [14]. A composition comprising the polypeptide of any of    paragraphs 1-13 and a stabilizer.-   Paragraph [15]. The composition of paragraph 14, wherein the    stabilizer is glycerol.-   Paragraph [16]. A use of the dextranase of any of the paragraphs    1-13, for reducing viscosity in a sugar solution.-   Paragraph [17]. A method for reducing viscosity in a sugar solution    comprising contacting the sugar solution with a dextranase of any of    paragraphs 1-13.-   Paragraph [18]. The method of paragraph 17, wherein the dextranase    is added before clarification, in holding juice tanks, before an    evaporator step, and/or in syrup tanks.-   Paragraph [19]. The method of any of paragraphs 17-18, wherein pH is    in the range from 4.0 to 8.0, particularly from 5.0 to 7.0, more    particularly from 5.5 to 6.5.-   Paragraph [20]. The method of any of paragraphs 17-19, wherein the    temperature is in the range from 30-65° C., particularly from 40-65°    C., more particularly from 50-65° C.-   Paragraph [21]. An isolated polynucleotide encoding the polypeptide    of any of paragraphs 1-13.-   Paragraph [22]. A nucleic acid construct or expression vector    comprising the polynucleotide of paragraph 21 operably linked to one    or more control sequences that direct the production of the    polypeptide in an expression host.-   Paragraph [23]. A recombinant host cell comprising the    polynucleotide of paragraph 21 operably linked to one or more    control sequences that direct the production of the polypeptide.-   Paragraph [24]. A method of producing a polypeptide having    dextranase activity, comprising:

(a) cultivating the host cell of paragraph 23 under conditions conducivefor production of the polypeptide; and

(b) recovering the polypeptide.

The present invention is further described by the following examplesthat should not be construed as limiting the scope of the invention.

EXAMPLES Strains

Aspergillus oryzae MT3568 strain was used for heterologous expression ofSEQ ID NO: 2, encoded from SEQ ID NO: 1. A. oryzae MT3568 is an amdS(acetamidase) disrupted gene derivative of Aspergillus oryzae JaL355 (WO2002/40694) in which pyrG auxotrophy was restored by disrupting the A.oryzae acetamidase (amdS) gene with the pyrG gene. Protoplasts ofAspergillus oryzae MT3568 were prepared according to WO 95/02043.

Strain CBS380.55 (isolated from forest soil in Patharia, India (1955)),Acrophialophora fusispora, was used as the source for the DNA encodingthe dextranase of SEQ ID NO: 2.

Media and Solutions

LB plates were composed of 10 g of Bacto-Tryptone, 5 g of yeast extract,10 g of sodium chloride, 15 g of Bacto-agar, and deionized water to 1liter.

LB medium was composed of 10 g of Bacto-Tryptone, 5 g of yeast extract,and 10 g of sodium chloride, and deionized water to 1 liter.

DAP-4C-1

-   11 g MgSO4,7H₂O-   1 g KH₂PO₄-   2 g C₆H₈O₇, H₂O-   20 g Dextrose-   10 g Maltose-   5.2 g K₃PO₄,H₂O-   0.5 g Yeast Extract-   0.5 ml KU6 Trace metal sol.(AMG) (MSA-SUB-FS-0042)-   Mix until completely solved-   1 ml Dowfax 63N10 was added-   Adjust volume with Milli-Q-water up to 1000 ml-   CaCO₃ tabl. á 0.5 g (add 1 tabl./200 ml)-   Before inoculation, each shake flask a 150 ml was added 3,5 ml    di-Ammoniumhydrogenphosphate (NH₄)₂HPO₄ 50%, and 5.0 ml Lactic acid    20%.    KU6 Trace metal sol.(AMG) (MSA-SUB-FS-0042)-   6.8 g ZnCl₂-   2.5 g CuSO₄.5H₂O-   0.13 g Nickel Chloride anhydrous-   13.9 g FeSO4.7H₂O-   8.45 g MnSO₄. H₂O-   3 g C₆H₈O₇.H₂O-   Ion exchanged water up to 1000 ml

Chem. 7-cif. Raw material formula Supplier no. Amount Zinc ChlorideZnCl₂ Merck 102- 6.8 g 108816 4965 Copper Sulfate CuSO₄•5H₂O Merck 109-2.5 g 102790 0771 Nickel Chloride NiCl2 Merck 101- 0.13 g anhydrous806722 6652 Iron Sulfate FeSO4•7H₂O Merck 13.9 g 103965 ManganeseSulfate MnSO₄•H₂O Merck 8.45 g 105941 Citric acid C₆H₈O₇•H₂O Merck 3 g100244 Ion exchanged water up 1000 ml to

COVE sucrose plates were composed of 342 g of sucrose, 20 g of agarpowder, 20 ml of COVE salt solution, and deionized water to 1 liter. Themedium was sterilized by autoclaving at 15 psi for 15 minutes(Bacteriological Analytical Manual, 8th Edition, Revision A, 1998). Themedium was cooled to 60° C. and 10 mM acetamide, Triton X-100 (50 μl/500ml) were added.

COVE salt solution was composed of 26 g of MgSO₄.7H₂O, 26 g of KCL, 26 gof KH₂PO₄, 50 ml of COVE trace metal solution, and deionized water to 1liter.

COVE trace metal solution was composed of 0.04 g of Na₂B₄O₇.10H₂O, 0.4 gof CuSO₄.5H₂O, 1.2 g of FeSO₄.7H₂O, 0.7 g of MnSO₄.H₂O, 0.8 g ofNa₂MoO₄.2H₂O, 10 g of ZnSO₄.7H₂O, and deionized water to 1 liter.

Example 1 Cloning, Expression and Fermentation of the Acrophialophorafusispora Dextranase

The gene (SEQ ID NO: 1) encoding the dextranase disclosed herein as SEQID NO: 2 was amplified by PCR. The PCR was composed of 1 μl of genomicDNA of the strain CBS380.55 Acrophialophora fusispora, 0.75 μl ofcloning primer forward (SEQ ID NO: 3) (10 μM), 0.75 μl of primer cloningprimer reverse (SEQ ID NO: 4) (10 μM), 3 μl of 5× HF buffer (FinnzymesOy, Finland), 0.25 μl of 50 mM MgCl₂, 0.30 μl of 10 mM dNTP, 0.15 μl ofPHUSION® DNA polymerase (Finnzymes Oy, Finland), and 8.8 μl PCR-gradewater. The amplification reaction was performed using a Thermal Cyclerprogrammed for 2 minutes at 98° C. followed by 30 cycles each at 98° C.for 15 seconds, 60° C. for 30 seconds, and 72° C. for 1 minutes and 30seconds; and 3 minutes at 72° C. The amplification reaction wasperformed using a Thermal Cycler programmed for 2 minutes at 98° C.followed by 35 cycles each at 98° C. for 10 seconds and 72° C. for 1minute and 30 seconds.

Dex5-F (SEQ ID NO: 3) 5′-ACACAACTGGGGATCCACCATGTTTTCTGTTCTTCTGGGCTGGC-3′Dex5-R (SEQ ID NO: 4) 5′-AGATCTCGAGAAGCTTATCAATTAATAGCCCACTGCCCCCA-3′

The PCR product was isolated on 1.0% agarose gel electrophoresis usingTAE buffer where the PCR band was excised from the gel and purifiedusing a GFX® PCR DNA and Gel Band Purification Kit (GE Healthcare,Hillerød Denmark) according to the manufacturer's instructions. DNAcorresponding to the Acrophialophora fusispora dextranase gene SEQ IDNO: 1 was cloned into the expression vector pDAu109 (WO2005/042735)previously linearized with Barn HI and Hind III, using an IN-FUSION™Dry-Down PCR Cloning Kit (BD Biosciences, Palo Alto, Calif., USA)according to the manufacturer's instructions.

A 1 μl volume of the undiluted ligation mixture was used to transform BDPhusion-Blue (Clontech). Two colonies were selected on LB agar platescontaining 100 μg of ampicillin per ml and cultivated overnight in 2 mlof LB medium supplemented with 100 μg of ampicillin per ml. Plasmid DNAwas purified using an Jetquick Plasmid Miniprep Spin Kit (Genomed GmbH,Løhne, Germany) according to the manufacturer's instructions. TheAcrophialophora fusispora dextranase gene sequence was verified bySanger sequencing before heterologous expression. One plasmid designatedas Dex5-1 (containing SEQ ID NO: 1) was selected for heterologousexpression of the dextranase gene in an Aspergillus oryzae MT3568 hostcell.

Aspergillus oryzae MT3568 strain was used for heterologous expression ofSEQ ID NO: 1/SEQ ID NO: 2. A. oryzae MT3568 is an amdS (acetamidase)disrupted gene derivative of Aspergillus oryzae JaL355 (WO 02/40694) inwhich pyrG auxotrophy was restored by disrupting the A. oryzaeacetamidase (amdS) gene with the pyrG gene. Protoplasts of Aspergillusoryzae MT3568 were prepared according to WO 95/002043.

One hundred μl of Aspergillus oryzae MT3568 protoplasts were mixed with1-2 μg of the Aspergillus expression vector with the cloned dextranasegene and 250 μl of 60% PEG 4000 (Applichem, Darmstadt, Germany)(polyethylene glycol, molecular weight 4,000), 10 mM CaCl₂, and 10 mMTris-HCl pH 7.5 and gently mixed. After 30 min of incubation at 37° C.,4 ml of topagar (temp. 40° C.) was added, and the protoplasts werespread onto COVE plates for selection. After incubation for 4-7 days at37° C. spores of four transformants were inoculated into 0.5 ml ofDAP-4C-01 medium in 96 deep well plates. After 4-5 days cultivation at30° C., the culture broths were analyzed by SDS-PAGE to identify thetransformants producing the largest amount of recombinant dextranasefrom CBS380.55 Acrophialophora fusispora, and the culture broths werealso analyzed in assays for confirmation of activity.

Spores of the best transformant were spread on COVE plates containing0.01% TRITON® X-100 in order to isolate single colonies. The spreadingwas repeated twice.

Fermentation for Purification

An Aspergillus oryzae transformant constructed as described above wasfermented in 150m1 DAP-4C-01 medium in 500 ml fluted shake flasksincubated at 30° C. in a shaking platform incubator rotating at 150 RPMfor 5 days and further used for assays as described below.

The enzyme was purified using Anion exchange chromatography usingstarting buffer A: 20 mM Phosphate pH 6.0 and elution with a 100%gradient of buffer B: same as A with 1 M NaCl. The eluted proteins weretested with AZCL-dextran substrate to confirm dextranase activity. Thepositive fractions were pooled and exchanged into 20 mM Tris Buffer, pH7.0.

Example 2 Dextranase Activity

The dextranase was successfully purified and the activity confirmed byAZCL-dextran.

Activity was measured by reducing ends at different temperature and pH.Dextran was used in 0.02% because of the background that generates whenusing reducing ends.

The dextranase according to the invention is active at a widepH/temperature range, with a maximum at T=62° C. and a pH optimum at5.5. The temperature profile is shown in FIG. 1.

LC-MS (Liquid Chromatography-Mass Spectrometry)

The analysis is performed using an LTQ Deca max IonTrap equipped with anESI source and an Accela HPLC system with a PDA detector. A BEH AcquityCSH C18 column (2.1×100 mm) is used for the separation at a flow rate of250 μL/min and 65° C. The gradient is as follows: A: 0.15% HCOOH inwater, B: HCOOH in MeCN; 0 min 17% B, 4 min 17% B, 14 min 24.3% B, 15min 95% B, 16 min 17% B, 20 min 17% B. 5 μL of samples is injected andUV detection is at 245 nm. The spray settings are as follows: Capillarytemp 275° C., sheath gas flow 40 l/min and source voltage of 5 kV.

The hydrolysis of dextran by dextranase was followed by LC-MS. Thereaction mixture was incubated at pH 7 and room temperature; atdifferent time points a sample was removed from the reaction mix andprecipitated with EtOH (1:2) for further preparation to LC-MS run. Thesubstrate dextran was 1% in the reaction mix and the enzymeconcentration 0.5 mg/mL. The results show that the main products ofhydrolysis under these conditions, is glucose monosaccharide followed bytetrasaccharide. The disaccharide is further hydrolyzed in time, whilethe tetrasaccharide and trisaccharide remain in the same level. Thecomplete hydrolysis is shown in FIG. 2. For each time point in thefigure the columns represent (in the same order): glucose, disaccharide,trisaccharide, tetrasaccharide respectively.

Example 3 Reduction in Viscosity in Synthetic Juice using the Dextranaseof the Invention Compared to a Commercial Dextranase Plus L. Materialsand Methods

Enzymatic hydrolysis

-   Samples    -   Synthetic juice and synthetic syrup prepared from white sugar        collected from Barra Grande Mill (from Zilor group);    -   0.25% (w/v) Dextran solution (prepared using Phosphate buffer pH        6.6 and Acetate buffer pH 5.5).-   Equipment    -   Analytical balances, Thermo-mixers (2-1.5mL), Micropipettes,        Vipr device, Eon Micro-plate Reader-   Chemicals    -   1 M phosphate buffer (pH 6.6 and 7.0), 1 M acetate buffer (pH        5.5), Tap water, Dextran from Leuconostoc spp (Sigma-Aldrich        09184-250G-F; the measured moisture was 7%);-   Enzymes    -   Dextranase Plus L (available from Novozymes A/S)    -   Dextranase from A. fusispora (SEQ ID NO: 2)

Hydrolysis was run in triplicate. Preparation of the synthetic syrup:the white sugar was dissolved in phosphate buffer 50 mM (pH 7) achievinga final pH 6.6 and final concentration of 50% w/w. Preparation ofsynthetic juice: the white sugar was dissolved in phosphate buffer 100mM (pH 6.6) achieving a final pH 6.5 and final concentration of 15% w/w(or alternatively dissolved in the acetate buffer 100 mM pH 5.5 andfinal concentration of 15% w/w). All synthetic syrup and juice samplesas well as dextran solution (using white sugar sample) were spiked withdextran to result in a final concentrations of 0.5% (w/v) for syrup and0.25% w/v for juice.

Aliquots were distributed equally in the tubes (final volumes of 1.5mL). The dose of enzymatic solution used in the case of syrup solutionwas 166 ppm; in case of juice and dextran solutions, enzymatic solutiondose of 16 ppm was applied (see the protein dose in the following).Tubes were incubated at 55° C. while enzymatic products were diluted(1:10 and 1:100) to be added in a dose volume of 2.5 microL. Afterenzyme addition, tubes were returned to the thermo-mixer at 55° C. underagitation (˜300 rpm) for 20 min for syrup, and 15 min for juice anddextran solutions. The reaction was stopped by incubation in boilingwater for 5 min, followed by ice bath.

For tubes without dextran, the same volume of water was added to keepall at the same dilution.

Viscosity Measurement

Viscosity measurement was performed using Vipr Technology at roomtemperature using Brand Tips 0-200 uL (speed 3; volume of 200 uL).Viscosity is usually measured by rheological instrument, such asBrookfield viscometer. The viscosity of a solution is a measure of therate of deformation upon exposure to shear stress (the force required togenerate a liquid flow). The ViPr technology is based on the pressuredrop needed to generate a liquid flow at constant velocity. This isachieved by measuring the pressure in the headspace of an automatedpipette (mViPr) during aspirating and dispensing. Thus, this technologyprovides a method of determining enzyme activity in a fluid, wherein theactivity over time provides a viscosity-change in the fluid, by the useof a device equipped with a pressure sensor to determine the change inthe fluid viscosity over time as a measure of the enzyme activity. Thistechnology has been described in detail in WO 2011/107472.

As an example of ViPr technology, the proportionality between themeasured pressure and viscosity (calibration curves) using the mViPrpipette is shown in FIG. 3. It corresponds to dispensation measurementsin Pascal of four viscosity standards (water and S6, N10, N35-Flukaviscosity and density standards) pipetting 200 μL using the 300 μLFinntip Extended tip (model: PMP-105-030J) at speed 4 and 5. Data ispresented as pressure [Pa] as a function of the actual viscosity [cp].

To validate the methodology presented, Table 1 shows values of viscosityof different samples of syrups measured using a Brookfield viscometerand mViPr pipette. Viscosity measurement on Brookfield viscometer (modelDV-II) was performed at 30° C., 60 rpm, using spindle 18 and the SSA(Small Sample Adapter) vessel. Vessel was load with 6 mL of sample, andtemperature was equilibrated at 30° C. (˜5 min) before taking thereadings.

TABLE 1 Viscosities of sugarcane (SC) syrup samples using Brookfieldviscosimeter and mViPr pipette. mViPr determinations using mViPr300pipette with a Finn tip 200 Extended tip (PMP-105-030J) andaspirate/dispense speed of 4. Volume = 200 μl ([Coefficient ofVariation]_(average) = 0.8%) Viscosity Viscosity Brookfield mViPrSamples (cP) (cP) SC syrup 1 10.6 10.38 SC syrup 2 12.5 11.32 SC syrup 311.3 10.19 SC syrup 4 11.8 10.03 SC syrup 5 11.5 9.63 SC syrup 6 12.210.57

Reducing Sugars Measurement

Dextranase assay measures the release of reducing sugars from dextranwith Ferricyanide reagent (adsorption at 420 nm). Procedure: add 190microL of each sample to be evaluated into 2 mL centrifuge tubes. Then,add 1.5 mL of ferricyanide reagent (20 g Na₂CO₃ and 0.4 g potassiumferricyanide dissolved into 1 L volumetric flask). The tubes wereincubated for 12 minutes at 96° C. and 300 rpm in a thermomixer(Eppendorf). Cool tubes in flow water and transfer 300 microL of eachtube to wells on microplate. Finally, read absorbance at 420 nm (EonMicroplate Reader).

FIG. 4 shows the performance of the two dextranase enzymes in reducingviscosity on synthetic syrup (50% w/w) enriched with dextran (0.5% w/v).The syrup was prepared using a phosphate buffer (pH 7.0) leading to asolution of pH 6.6. The enzyme dose was 1.08 ppm (w/v) for thecommercial product (Dextranase Plus L) and 0.25 ppm (w/v) for the A.fusispora dextranase (approx. 4-fold lower). The incubation conditionwas 55° C. for 20 min. The viscosity was measured by the Viprtechnology. The Vipr pipette provided pressure measurements duringaspirating and dispensing the samples. Parameters for the use of Viprpipette were speed 3, aspired/dispensed volume of 200 uL and tip usedwas a Brand 0-200 uL.

The values of pressure shown in FIG. 4 correspond to a Delta Pressure,i.e., the difference between the minimum and maximum pressure foraspiration and dispense for a given sample. These values areproportional to viscosity within a certain dynamic viscosity range whichdepends on speed and tip diameter. In principle, aspiration and dispensepressures should be equal; however, contribution from gravity results inslightly higher numerical values for aspiration compared to dispense.One important parameter is the set point of the ambient pressure (thatmust be constant during the whole period of the analysis). Because weverified that a small variation on the set point during the day of theanalysis was interfering in obtaining reproductive and comparablemeasurements, we decided to use the delta Pressure.

FIG. 5 shows the performance of the two dextranase enzymes acting onsynthetic juice (15% w/w) enriched with dextran (0.25% w/v). Theperformance is evaluated by the concept of dextrose equivalent (DE).Note that at this evaluation, the sugar sample was dissolved in 0.1 Macetate buffer pH 5.5, which is the pH normally found for this type ofsubstrate in Sugar Mills. All samples are submitted by the treatmentunder conditions of 55° C.; pH 5.5 (acetate buffer); 15 min. When noenzymes are added to samples (first two bars in FIG. 5), one can seeonly a very small difference of DE (or absorbance) between the sampleenriched with dextran and the one without dextran. Hence, insignificantamount of reducing sugar is derived from the breaking down of dextrandue to the methodology applied. In case of samples with enzymes, blanksrefer to the sample with addition of the respective denatured enzyme(enzymes are put in boiling water for 5 min, followed by ice bath). Acomparison among the blanks and sample with no enzyme confirm theeffectiveness of the denaturing process of enzyme. The initial amount ofdextran is 0.25% w/w. FIG. 5 shows low DE for blanks and the efficiencyof the two dextranase can be compared by the difference found betweenrespective bars. The same amount of protein—0.025 ppm (w/v))—for theapplication of each enzymatic products (Plus L and A. fusispora samples)was added to respective tubes. FIG. 5 shows that, under the same enzymeconcentration, the enzyme derived from A. fusispora has the highestactivity for dextran among the evaluated samples (higher dextroseequivalent measured in the substrate after hydrolysis of 15 minutes at55° C. and pH 5.5). In terms of dextrose equivalent, which reflects thebreaking of high MW dextran molecule in the substrate (i.e., an indirectmeasure of reducing the viscosity), the enzyme derived from A. fusisporashows a performance of 23% higher than that demonstrated by commercialsample Plus L (that means an increase in DE content).

FIG. 6 shows the performance of the two dextranase enzymes actingdirectly on dextran solution (0.25% w/v) using acetate buffer 0.1 M andpH 5.5, which is the pH value usually found for this kind of substratein Sugar Mills. The performance was evaluated by the concept of dextroseequivalent. Samples were incubated at 55° C.; pH 5.5; 15 min. Again,when no enzymes were added to samples, only a very small difference ofDE between the sample enriched with dextran and the one without dextranwas observed (i.e., insignificant amount of reducing sugar was derivedfrom breaking down dextran due to the methodology applied on thismatrix). A protein dose of 0.025 ppm (w/v) for the application of eachenzymatic product (Plus L and A. fusispora samples) was used in theassay. One can see from FIG. 6 that, under the same enzymeconcentration, the enzyme derived from A. fusispora has the highestactivity for dextran among the evaluated samples (higher dextroseequivalent measured in the substrate after hydrolysis of 15 minutes at55° C. and pH 5.5). In terms of dextrose equivalent, the enzyme derivedfrom A. fusispora showed a performance of 36% higher than thatdemonstrated by commercial sample Plus L. This value is higher than theperformance found for the case of synthetic juice.

Example 4 Comparative Example of Viscosity Reduction in Synthetic Juice,Sugarcane Syrup, and Synthetic Syrup, using the Dextranase from A.fusispora and a Commercial Dextranase, Dextranase Plus L

Performance was tested on synthetic juice (15% w/w), sugarcane syrup(54.8° Brix; collected from a Sugarcane Mill) and synthetic syrup (50%w/w), all enriched with dextran (0.5% w/v).

Enzymatic Hydrolysis

-   Samples    -   Synthetic juice and synthetic syrup prepared from white sugar        collected from Sugar Mill 1;    -   Syrup collected from Sugar Mill 1;    -   0.5% (w/v) Dextran solution.-   Equipment    -   Analytical balances, Incubators (rotisseries), Micropipettes,        Brookfield viscometer (Dv2T LV), Eon Microplate Reader-   Chemicals    -   1 M phosphate buffer (pH 6.6), 1 M acetate buffer (pH 5.5), Tap        water, Dextran from Leuconostoc spp (Sigma-Aldrich 09184-250G-F;        the measured moisture was 7%);-   Enzymes    -   Dextranase Plus L (Sequoia database: Z4T4Z/U7319; commercial        product from NZ);    -   Experimental Dextranase from A. fusispora (Sequoia database:        Z4TFB/U76FS);

Experiments of hydrolysis were run in triplicate. Preparation ofsynthetic syrup: white sugar was dissolved in phosphate buffer 50 mM (pH6.6) at final concentration of 50% w/w. Preparation of synthetic juice:white sugar was dissolved in acetate buffer 100 mM (pH 5.5) at finalconcentration of 15% w/w. All synthetic syrup and juice samples werespiked with dextran to result in a final concentrations of 0.5%(w/v).

Aliquots were distributed equally in the tubes (final volumes of 20 mL).In case of syrup, enzyme dose was 166 ppm. In case of juice, enzyme doseof 16 ppm was used. Tubes were incubated at 55° C. while enzymes werediluted to be added in a correct dose. After enzyme addition, tubes werereturned to the incubator at 55° C. under agitation (≠25 rpm) for 30min. The reaction was stopped by incubation in boiling water for 5 min,followed by cooling on ice.

For the tubes without dextran, the same volume of water was added tokeep all at the same dilution.

Viscosity Measurement: Brookfiled Viscometer.

Viscosity measurement was performed using Brookfiled viscometer DV2TLV,SSA (small sample adapter) at 25° C. (Spindle SC4-18/13R; sample volume:6.7 mL). Results:

TABLE 2a Measured viscosity of synthetic juice (15% w/w) enriched withdextran (0.5% w/v); incubated with dextranase enzymes. Conditions: 55°C.; pH 5.5 (0.1M acetate buffer); 30 min. Viscosity is measured usingBrookfield viscometer. Enzyme dose: 16 ppm. Protein content (μg/mL):Plus L = 0.108 μg/mL; A. fusispora = 0.025 μg/mL (note 4-fold lower thancommercial). Dextranase A. fusispora Sugar Plus L Enzyme Viscosity, cpJuice (0.108 μg/mL) (0.025 μg/mL) with no Dextran 1.56 ± 0.03 1.62 ±0.06 1.55 ± 0.02 with 0.5% w/v 2.22 ± 0.04 1.73 ± 0.04 2.00 ± 0.03Dextran

TABLE 2b Results calculated as % reduction. Dextranase A. fusispora PlusL Enzyme Viscosity reduction, % 75.3 ± 5.4% 33.8 ± 3.8% Protein Dose(μg/mL) 0.108 0.025

TABLE 3a Measure viscosity of sugarcane syrup (54.8° Brix; collectedfrom a Sugarcane Mill) enriched with dextran (0.5% w/v); incubated withdextranase enzymes. Conditions: 55° C.; pH 6.6 (0.1M phosphate buffer);30 min. Viscosity is measured using Brookfield viscometer. Enzyme dose:166 ppm. Protein content (μg/mL): Plus L = 1.08 μg/mL; A. fusispora =0.25 μg/mL (note 4-fold lower than commercial) Dextranase A. fusisporaReal Plus L Enzyme Viscosity, cp Syrup (1.08 μg/mL) (0.25 μg/mL) with noDextran 30.76 ± 0.82 30.70 ± 1.03 30.72 ± 0.69 with 0.5% w/v 43.66 ±0.51 31.30 ± 1.65 32.66 ± 1.42 Dextran

TABLE 3b Results calculated as % reduction. Dextranase A. fusispora PlusL Enzyme Viscosity reduction, % 95.6 ± 12.8% 85.1 ± 11.0% Protein Dose(μg/mL) 1.08 0.25

TABLE 4a Measure viscosity profile of synthetic syrup (50° Brix)enriched with dextran (0.5% w/v); incubated with dextranase enzymes.Conditions: 55° C.; pH 6.6 (50 mM phosphate buffer); 30 min. Viscosityis measured using Brookfield viscometer. Enzyme dose: 166 ppm. Proteincontent (μg/mL): Plus L = 1.08 μg/mL; A. fusispora = 0.25 μg/mL (note4-fold lower than commercial) Sugar Dextranase A. fusispora Viscosity,cp Syrup Plus L Enzyme with no Dextran 12.51 ± 0.55 12.16 ± 1.07 12.57 ±0.40 with 0.5% w/v 18.41 ± 0.31 13.53 ± 0.08 13.85 ± 0.02 Dextran

TABLE 4b Results calculated as % reduction. Dextranase A. fusispora PlusL Enzyme Viscosity reduction, % 81.8 ± 1.3% 76.5 ± 0.39% Protein Dose(ug/mL) 1.08 0.25

Example 5 Comparative Example of Temperature Profiles for DextranaseEnzymes in Viscosity Reduction of Sugarcane Syrup, and Sugar Cane Juice,using the Dextranase from A. fusispora and a Commercial Dextranase,Dextranase Plus L

Performance was tested on sugarcane syrup (48° Brix; collected from aSugarcane Mill) and sugarcane juice (17.6% w/w), both enriched withdextran (0.5% w/v).

The performance of two dextranases—Dextranase Plus L, and the dextranasefrom A. fusispora—was investigated for reducing viscosity of real juiceand syrup from Sugarcane Mills containing 0.5% w/v dextran. Themeasurement of viscosity after enzymatic hydrolysis is performed by theBrookfield Viscometer (DV2T-LV). Temperature profiles: 50° C., 60° C.,70° C., 78° C.

Enzymatic hydrolysis

-   Samples    -   Syrup collected from Sugarcane Mill 2—1GBR23 (Syrup)—pH 5.954        and 48.08° Brix    -   Juice collected from Sugarcane Mill 1 (primary Juice)-pH 5.256        and 17.59° Brix-   Equipment    -   Analytical balances, Centrifuges, Thermostatic Bath with        agitation (speed 30), Micropipettes, Brookfield Viscometer        (DV2T-LV), vacuum filtration.-   Chemicals    -   Dextran from Leuconostoc spp (Sigma-Aldrich 09184-250G-F)-   Enzymes    -   Dextranase Plus L    -   Dextranase from A. fusispora

Hydrolysis were run in duplicate. Syrup and juice samples were spikedwith dextran to result in final concentrations of 0.5% (w/v). In case ofjuice, the sample corresponds to the primary juice, and has beenfiltered using glass filter to eliminate any particulate matter andbagacillo.

Aliquots were distributed equally in the tubes (final volumes of 10 mL).In case of syrup, enzyme dose was 100 ppm Plus L and 424 ppm A.fusispora (this ensure the same protein content in final syrup solution:0.650 μg/mL syrup; Plus L=6.53 mg/mL product; A. fusispora=1.54 mg/mLproduct). In case of juice enzyme dose of 10 ppm and 42.4 ppm for Plus Land A. fusispora, respectively, were used. After enzyme addition, tubeswere incubated in Thermostatic bath with agitation at differenttemperatures under agitation (30 min⁻¹) for 25 min. The reaction isstopped by incubation in boiling water for 5 min, followed by cooling onice (at least, 15 min).

For the tubes without dextran, the same volume of water was added tokeep all at the same dilution.

Viscosity Measurement

Viscosity measurement was performed using Brookfield Viscometer DV2T-LV,at 25° C., using spindle 18 and the SSA (Small Sample Adapter) vessel.Volume of sample standardized to 6.7 ml.

Results:

TABLE 5a Viscosity values (performance) of dextranase enzymes inreducing viscosity on sugarcane syrup (48% w/w) enriched with dextran(0.5% w/v), at different temperatures. Condition: pH 6.0; 25 min,agitation 30 min⁻¹. Viscosity is measured using Brookfield viscometer.Dose/Protein content: 0.650 μg/mL. Viscosity of the Sugarcane syrup:11.46 ± 0.51 cp with no Dextran; and 13.56 ± 0.21 cp with 0.5% w/vDextran. Viscosity, cp 50° C. 60° C. 70° C. 78° C. Dextranase 11.56 ±0.40 12.05 ± 0.57 12.10 ± 0.06 11.53 ± 0.53 Plus L A. fusispora 11.64 ±0.30 11.73 ± 0.30 11.85 ± 0.04 12.00 ± 0.25 enzyme

TABLE 5b Results calculated as % reduction. Viscosity Dextranasereduction, % Plus L A. fusispora 50° C. 95 ± 19% 91 ± 14% 60° C. 72 ±27% 87 ± 14% 70° C. 69 ± 03% 81 ± 02% 78° C. 96 ± 25% 74 ± 12%

TABLE 6a Viscosity values (performance) of dextranase enzymes inreducing viscosity on sugarcane juice (17.6% w/w) enriched with dextran(0.5% w/v), at different temperatures. Condition: pH 5.2; 25 min,agitation 30 min⁻¹. Viscosity was measured using Brookfield viscometer.Dose/Protein content: 0.065 μg/mL. Viscosity of the Sugarcane juice:1.645 ± 0.007 cp with no dextran, and 1.915 ± 0.007 cp with 0.5% w/vdextran. Viscosity, cp 50° C. 60° C. 70° C. 78° C. Dextranase 1.74 ±0.01 1.74 ± 0.01 1.77 ± 0.01 1.83 ± 0.01 Plus L A. fusispora 1.73 ± 0.011.73 ± 0.01 1.76 ± 0.01 1.81 ± 0.01 enzyme

TABLE 6b Results calculated as % reduction Dextranase A. fusispora TempPlus L enzyme 50° C. 67 ± 03% 68 ± 00% 60° C. 67 ± 03% 68 ± 00% 70° C.54 ± 00% 55 ± 03% 78° C. 33 ± 03% 38 ± 05%

Example 6 Comparative Kinetic Study of Dextranase Enzymes in ViscosityReduction of Sugarcane Syrup using the Dextranase from A. fusispora anda Commercial Dextranase, Dextranase Plus L

Kinetic studies of dextranase enzymes on sugarcane syrup (61° Brix;collected from a Sugarcane Mill 1) enriched with dextran (1% w/v).

The kinetic performance of two dextranases, Dextranase Plus L anddextranase from A. fusispora, was investigated for reducing viscosity ofsyrup from Sugarcane Mills containing 1% w/v dextran. The measurement ofviscosity after enzymatic hydrolysis is performed by the BrookfieldViscometer (DV2T-LV). The temperature of incubation was 55° C.

Enzymatic Hydrolysis

-   Samples    -   Syrup collected from Sugarcane Mill 1-pH 5.6 adjusted to 6.5 and        61° Brix-   Equipment    -   Analytical balances, Centrifuges, Thermostatic Bath with        agitation (speed 30), Micropipettes, Brookfield Viscometer        (DV2T-LV), vacuum filtration.-   Chemicals    -   Dextran from Leuconostoc spp (Sigma-Aldrich 09184-250G-F)-   Enzymes    -   Dextranase Plus L    -   Dextranase from A. fusispora

Experiments of kinetic hydrolysis were carried out at SSA vesselBrookfield Viscometer. Syrup was spiked with dextran to result in afinal concentration of 1% (w/v).

A volume of 6.7 mL syrup was added to the SSA and the solutiontemperature was allowed to stabilize at 55° C. (then, initial viscosityof syrup was taken). Then, dextranase enzyme was added and the viscosityreduction was recorded as function of time (at least 22 min incubationtime). The protein content in final syrup solution was 0.650 μl/ml syrupfor both Plus L and A. fusispora. Some agitation was ensured by therotation of the Brookfield spindle when it allowed the shear ratemeasurements (about 50 rpm).

For the control samples with and without dextran, the same volume ofwater was added to keep all at the same dilution.

Viscosity Measurement

Viscosity measurement was performed using Brookfield Viscometer DV2T-LV,at 55° C., using spindle 18 and the SSA (Small Sample Adapter) vessel.Volume of sample standardized to 6.7 ml.

The experiment was repeated twice.

Result of First Run:

Viscosity, cp Time Dextranase A. fusispora Temperature (min) Plus LEnzyme (° C.) 0.00 22.42 22.26 54.9 1.00 21.3 20.64 54.9 2.00 20.6420.28 54.9 3.00 20.58 20.16 54.9 4.00 20.46 20.04 54.9 5.00 20.4 19.9854.9 6.00 20.34 19.92 54.9 7.00 20.34 19.86 54.9 8.00 20.28 19.8 54.99.00 20.28 19.8 54.9 10.00 20.28 19.74 54.9 11.00 20.22 19.68 54.9 12.0020.22 19.62 54.9 13.00 20.22 19.62 54.9 14.00 20.22 19.56 54.9 15.0020.16 19.56 54.9 16.00 20.16 19.5 54.9 17.00 20.16 19.5 54.9 18.00 20.1619.44 54.9 19.00 20.16 19.44 54.9 20.00 20.16 19.38 54.9 21.00 20.1619.38 54.9 22.00 20.16 19.38 54.9 end 19.38 19.02 55.0

Result of Second Run:

Viscosity, cp Time Dextranase A. fusispora Temperature (min) Plus Lenzyme (° C.) 0.00 22.32 22.36 1.00 20.76 20.82 54.8 2.00 20.52 19.6854.8 3.00 20.46 19.5 54.8 4.00 20.34 19.44 54.9 5.00 20.22 19.38 54.96.00 20.16 19.32 54.9 7.00 20.1 19.2 54.8 8.00 20.04 19.14 54.8 9.0020.04 19.08 54.8 10.00 19.98 19.02 54.9 11.00 19.98 18.96 54.9 12.0019.92 18.96 54.9 13.00 19.8 18.96 55.0 14.00 19.74 18.96 55.0 15.0019.74 18.96 55.0 16.00 19.68 18.9 54.9 17.00 19.68 18.9 54.9 18.00 19.6818.9 54.9 19.00 19.68 18.9 54.9 20.00 19.68 18.9 54.8 21.00 19.68 18.8454.9 22.00 19.68 18.84 54.9 end 19.02 18.84 54.9

The invention described and claimed herein is not to be limited in scopeby the specific aspects herein disclosed, since these aspects areintended as illustrations of several aspects of the invention. Anyequivalent aspects are intended to be within the scope of thisinvention. Indeed, various modifications of the invention in addition tothose shown and described herein will become apparent to those skilledin the art from the foregoing description. Such modifications are alsointended to fall within the scope of the appended claims. In the case ofconflict, the present disclosure including definitions will control.

1-15. (canceled)
 16. A composition comprising a polypeptide havingdextranase activity and a stabilizer, wherein the amino acid sequence ofthe polypeptide has at least 92% sequence identity to the sequence ofamino acids 17 to 594 of SEQ ID NO:
 2. 17. The composition of claim 16,wherein the amino acid sequence of the polypeptide has at least 95%sequence identity to the sequence of amino acids 17 to 594 of SEQ ID NO:2.
 18. The composition of claim 16, wherein the amino acid sequence ofthe polypeptide has at least 97% sequence identity to the sequence ofamino acids 17 to 594 of SEQ ID NO:
 2. 19. The composition of claim 16,wherein the amino acid sequence of the polypeptide has at least 98%sequence identity to the sequence of amino acids 17 to 594 of SEQ ID NO:2.
 20. The composition of claim 16, wherein the polypeptide comprisesthe amino acid sequence of amino acids 17 to 594 of SEQ ID NO:
 2. 21.The composition of claim 16, wherein the polypeptide is a fragment ofthe amino acid sequence of amino acids 17 to 594 of SEQ ID NO: 2,wherein the fragment has dextranase activity.
 22. The composition ofclaim 16, wherein the stabilizer is glycerol.
 23. The composition ofclaim 17, wherein the stabilizer is glycerol.
 24. The composition ofclaim 18, wherein the stabilizer is glycerol.
 25. The composition ofclaim 19, wherein the stabilizer is glycerol.
 26. The composition ofclaim 20, wherein the stabilizer is glycerol.
 27. The composition ofclaim 21, wherein the stabilizer is glycerol.
 28. The composition ofclaim 16, wherein the stabilizer is trisodium citrate dihydrate.
 29. Thecomposition of claim 17, wherein the stabilizer is trisodium citratedihydrate.
 30. The composition of claim 18, wherein the stabilizer istrisodium citrate dihydrate.
 31. The composition of claim 19, whereinthe stabilizer is trisodium citrate dihydrate.
 32. The composition ofclaim 20, wherein the stabilizer is trisodium citrate dihydrate.
 33. Thecomposition of claim 21, wherein the stabilizer is trisodium citratedihydrate.